Differential function of phosphodiesterase families in the brain: Gaining insights through the use of genetically modified animals

Progress in Brain Research

Volumn 179, Issue C, 2009, Pages 67-73

  Kelly, Michele P ^a   Brandon, Nicholas J ^a  

^a PFIZER INC   (United States)

Author keywords

cAMP; cGMP; Cyclic nucleotide; Intracellular signaling; Knockout; Mouse model; Mutant; Phosphodiesterase; Psychiatry; Schizophrenia; Second messenger; Transgenic

Indexed keywords

CYCLIC NUCLEOTIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 1; PDE10A PROTEIN, MOUSE; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV;

ANIMAL; BRAIN LEVEL; CLASSIFICATION; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; BRAIN CHEMISTRY; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NUCLEOTIDES, CYCLIC; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 77953397255     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/S0079-6123(09)17908-6     Document Type: Article

References (48)

1. Barad, M., Blouin, A. M., & Cain, C. K. (2004). Like extinction, latent inhibition of conditioned fear in mice is blocked by systemic inhibition of L-type voltage-gated calcium channels. Learning & Memory, 11, 536-539.
2. Bender, A. T., & Beavo, J. A. (2006). Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacological Reviews, 58, 488-520.
3. Brandon, N. J., & Rotella, D. P. (2007). Potential CNS applications for phosphodiesterase enzyme inhibitors. In J. E. Macor (Ed.), Annual reports in medicinal chemistry (Vol. 42, Chapter 1) (pp. 3-12). USA: Elsevier. pp.
4. Clapcote, S. J., Lipina, T. V., Millar, J. K., Mackie, S., Christie, S., Ogawa, F., et al. (2007). Behavioral phenotypes of Disc1 missense mutations in mice. Neuron, 54, 387-402.
5. Cygnar, K. D., & Zhao, H. (2009). Phosphodiesterase 1C is dispensable for rapid response termination of olfactory sensory neurons. Nature Neuroscience, 12, 454-462.
6. DeMarch, Z., Giampa, C., Patassini, S., Bernardi, G., & Fusco, F. R. (2008). Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiology of Disease, 30, 375-387.
7. DeMarch, Z., Giampa, C., Patassini, S., Martorana, A., Bernardi, G., & Fusco, F. R. (2007). Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiology of Disease, 25, 266-273.
8. Dlaboga, D., Hajjhussein, H., & O'Donnell, J. M. (2006). Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: Comparison with rolipram. Brain Research, 1096, 104-112.
9. Dlaboga, D., Hajjhussein, H., & O'Donnell, J. M. (2008). Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum. Neuropharmacology, 54, 745-754.
10. Ehrman, L. A., Williams, M. T., Schaefer, T. L., Gudelsky, G.A., Reed, T. M., Fienberg, A. A., et al. (2006). Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: Evidence from PDE1B-DARPP32 double-knockout mice. Genes, Brain, & Behavior, 5, 540-551.
11. Engels, P., Abdel'Al, S., Hulley, P., & Lubbert, H. (1995). Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase. Journal of Neuroscience Research, 41, 169-178.
12. Fatemi, S. H., King, D. P., Reutiman, T. J., Folsom, T. D., Laurence, J. A., Lee, S., et al. (2008). PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophrenia Research, 101, 36-49.
13. Giampa, C., Middei, S., Patassini, S., Borreca, A., Marullo, F., Laurenti, D., et al. (2009a). Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. European Journal of Neuroscience, 29, 902-910.
14. Giampa, C., Patassini, S., Borreca, A., Laurenti, D., Marullo, F., Bernardi, G., et al. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiology of Disease, 34, 450-456.
15. Grauer S., Pulito P., Navarra R, Kelly MP, Kelley C., Graf R., et al. (in press) PDE10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. JPET. Epub ahead of print.
16. Hebb, A. L., Robertson, H. A., & Denovan-Wright, E. M. (2004). Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience, 123, 967-981.
17. Houslay, M. D., & Milligan, G. (1997). Tailoring cAMPsignalling responses through isoform multiplicity. Trends in Biochemical Sciences, 22, 217-224.
18. Houslay, M. D., Schafer, P., & Zhang, K. Y. (2005). Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discovery Today, 10, 1503-1519.
19. Hu, H., McCaw, E. A., Hebb, A. L., Gomez, G. T., & Denovan-Wright, E. M. (2004). Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. European Journal of Neuroscience, 20, 3351-3363.
20. Iona, S., Cuomo, M., Bushnik, T., Naro, F., Sette, C., Hess, M., et al. (1998). Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: Identification and differential expression of immunologically distinct forms in the rat brain. Molecular Pharmacology, 53, 23-32.
21. Kanes, S. J., Tokarczyk, J., Siegel, S. J., Bilker, W., Abel, T., & Kelly, M. P. (2007). Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience, 144, 239-246.
22. Kelly, M. P., Cheung, Y. F., Favilla, C., Siegel, S. J., Kanes, S.J., Houslay, M. D., et al. (2008). Constitutive activation of the G-protein subunit Galphas within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression. Learning & Memory, 15, 75-83.
23. Kelly, M. P., Isiegas, C., Cheung, Y. F., Tokarczyk, J., Yang, X., Esposito, M. F., et al. (2007). Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. Neuropsychopharmacology, 32, 577-588.
24. Kelly, M. P., Stein, J. M., Vecsey, C. G., Favilla, C., Yang, X., Bizily, S. F., et al. (2009). Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia. Molecular Psychiatry, 14, 398-415.
25. Lugnier, C. (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacology & Therapeutics, 109, 366-398.
26. Menniti, F. S., Chappie, T. A., Humphrey, J. M., & Schmidt, C.J. (2007). Phosphodiesterase 10A inhibitors: A novel approach to the treatment of the symptoms of schizophrenia. Current Opinion in Investigational Drugs, 8, 54-59.
27. Millar, J. K., Pickard, B. S., Mackie, S., James, R., Christie, S., Buchanan, S. R., et al. (2005). DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science, 310, 1187-1191.
28. Murdoch, H., Mackie, S., Collins, D. M., Hill, E. V., Bolger, G.B., Klussmann, E., et al. (2007). Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. Journal of Neuroscience, 27, 9513-9524.
29. O'Donnell, J. M., & Frith, S. (1999). Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacology, Biochemistry & Behavior, 63, 185-192.
30. Perez-Torres, S., Miro, X., Palacios, J. M., Cortes, R., Puigdomenech, P., & Mengod, G. (2000). Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. Journal of Chemical Neuroanatomy, 20, 349-374.
31. Pickard, B. S., Thomson, P. A., Christoforou, A., Evans, K. L., Morris, S. W., Porteous, D. J., et al. (2007). The PDE4B gene confers sex-specific protection against schizophrenia. Psychiatric Genetics, 17, 129-133.
32. Polli, J. W., & Kincaid, R. L. (1994). Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. Journal of Neuroscience, 14, 1251-1261.
33. Reed, T. M., Repaske, D. R., Snyder, G. L., Greengard, P., & Vorhees, C. V. (2002). Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. Journal of Neuroscience, 22, 5188-5197.
34. Rutten, K., Misner, D. L., Works, M., Blokland, A., Novak, T.J., Santarelli, L., et al. (2008). Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice. European Journal of Neuroscience, 28, 625-632.
35. Sano, H., Nagai, Y., Miyakawa, T., Shigemoto, R., & Yokoi, M. (2008). Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. Journal of Neurochemistry, 105, 546-556.
36. Silvestre, J. S., Fernandez, A. G., & Palacios, J. M. (1999). Effects of rolipram on the elevated plus-maze test in rats: A preliminary study. Journal of Psychopharmacology, 13, 274-277.
37. Siuciak, J. A., Chapin, D. S., McCarthy, S. A., & Martin, A. N. (2007a). Antipsychotic profile of rolipram: Efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology, 192, 415-424.
38. Siuciak, J. A., McCarthy, S. A., Chapin, D. S., Fujiwara, R. A., James, L. C., Williams, R. D., et al. (2006). Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function. Neuropharmacology, 51, 374-385.
39. Siuciak, J. A., McCarthy, S. A., Chapin, D. S., & Martin, A. N. (2008a). Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology, 197, 115-126.
40. Siuciak, J. A., McCarthy, S. A., Chapin, D. S., Martin, A. N., Harms, J. F., & Schmidt, C. J. (2008b). Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background. Neuropharmacology, 54, 417-427.
41. Siuciak, J. A., McCarthy, S. A., Chapin, D. S., Reed, T. M., Vorhees, C. V., & Repaske, D. R. (2007b). Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology, 53, 113-124.
42. Takahashi, M., Terwilliger, R., Lane, C., Mezes, P. S., Conti, M., & Duman, R. S. (1999). Chronic antidepressant administration increases the expression of cAMPspecific phosphodiesterase 4A and 4B isoforms. Journal of Neuroscience, 19, 610-618.
43. Turetsky, B. I., & Moberg, P. J. (2009). An odor-specific threshold deficit implicates abnormal intracellular cyclic AMP signaling in schizophrenia. American Journal of Psychiatry, 166, 226-233.
44. Yan, C., Bentley, J. K., Sonnenburg, W. K., & Beavo, J. A. (1994). Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. Journal of Neuroscience, 14, 973-984.
45. Yan, C., Zhao, A. Z., Bentley, J. K., Loughney, K., Ferguson, K., & Beavo, J. A. (1995). Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proceedings of the National Academy of Sciences of the United States of America, 92, 9677-9681.
46. Zhang,H. T., Crissman, A.M., Dorairaj,N. R., Chandler,L. J., & O'Donnell, J. M. (2000). Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology, 23, 198-204.
47. Zhang, H. T., Huang, Y., Jin, S. L., Frith, S. A., Suvarna, N., Conti, M., et al. (2002). Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology, 27, 587-595.
48. Zhang, H. T., Huang, Y., Masood, A., Stolinski, L. R., Li, Y., Zhang, L., et al. (2008). Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology, 33, 1611-1623.